

Target Name	HIV-1 protease
Target TTD ID	TTDS00319

Target Species	Human immunodeficiency virus 1
Chemical Type	N-Aryl Heteroarylisopropanolamines
Mode of Action	Inhibitor
QSAR Model 1	$pIC_{50} = -4.284 - (0.659)*Sfit + (0.010)*Dip-mom - (0.340)*HOMO + (0.008)*MW + (0.008)*Volume - (0.053)*G\_CDS\_aq$
Molecular Descriptor	<p>Access the following web-servers to compute molecular descriptors: <a href="#">MoDel</a> and <a href="#">e-dragon</a></p> <p>Parameter - description: Sfit - Steric fit between ligand and receptor; Dip-Mom - Dipole moment (AMSOL); HOMO - HOMO ligand energy (AMSOL); MW - Molecular weight (AMSOL); Volume - Molecular volume (AMSOL); G_CDS_aq - Cavity-dispersion-solvent free energy (AMSOL).</p>
Reference	Design, Synthesis and QSAR Studies on N-Aryl Heteroarylisopropanolamines, a New Class of Non-Peptidic HIV-1 Protease Inhibitors. <i>Bioorganic &amp; Medicinal Chemistry</i> 10 (2002) 2511–2526

Target Species	Human immunodeficiency virus 1
Chemical Type	Six-membered cyclic ureas
Mode of Action	Inhibitor
QSAR Model 1	$\log(1/K_i) = 2.139(\pm 0.740) + 0.167(\pm 0.018) {}^1SIC$

	$R^2 = 0.646; R_{cv}^2 = 0.617; s = 0.750; F = 90.$
QSAR Model 2	$\log(1/K_i) = 2.168(\pm 0.535) + 0.108(\pm 0.010)^2 SIC$ $+ 12.750(\pm 1.848)^{HD}FPSA^{(2)}$ $R^2 = 0.816; R_{cv}^2 = 0.792; s = 0.545; F = 107$
QSAR Model 3	$\log(1/K_i) = 15.901(\pm 0.917) + 261.881(\pm 24.823)^{HD}FCPSA^{(2)}$ $- 160.948(\pm 36.184)I^A - 5.708(\pm 0.746)J$ $R^2 = 0.855; R_{cv}^2 = 0.832; s = 0.489; F = 92$
QSAR Model 4	$\log(1/K_i) = 42.585(\pm 8.445) + 15.601(\pm 1.776)^{HD}FPSA^{(2)}$ $- 141.775(\pm 34.923)I^A - 6.204(\pm 0.732)J$ $- 0.234(\pm 0.073)E_{e-n}^{min}(O-H)$ $R^2 = 0.873; R_{cv}^2 = 0.847; s = 0.463; F = 79$
Molecular Descriptor	<p>Access the following web-servers to compute molecular descriptors: <a href="#">MoDel</a> and <a href="#">e-dragon</a></p> <p>Structural information content of order 1 (<sup>1</sup>SIC) accounts for both molecular constitutional and structural diversity. <sup>HD</sup>FPSA<sup>(2)</sup> (fractional positive surface area of hydrogen donors). <sup>H</sup>FPSA<sup>(2)</sup> (fractional positive surface area of hydrogen donor species). The hydrogen bond descriptor <sup>HD</sup>FCPSA<sup>(2)</sup> which is a charge weighted analogue of <sup>HD</sup>FPSA<sup>(2)</sup> (weighted by Zefirov's atomic charges). First moment of inertia (I<sup>A</sup>). Balaban topological index J, a measure of molecular 'centricity'.</p> <p>The minimum electronuclear attraction energy for O-H bond, <math>E_{e-n}^{min}(O-H)</math>, which may be regarded as an immediate scale of the bond strength.</p>
Reference	Six-Membered Cyclic Ureas as HIV-1 Protease Inhibitors: A QSAR Study Based on CODESSA PRO Approach. <i>Bioorganic &amp; Medicinal Chemistry Letters</i> 12 (2002) 3453–3457

Target Species	Human immunodeficiency virus 1
-------------------	--------------------------------

<b>Chemical Type</b>	Alkyl substituted P2/P2' 3-aminoindazoles
<b>Mode of Action</b>	Inhibitor
<b>QSAR Model 1</b>	$\text{Log } 1/K_i = -0.39(\pm 0.22)\text{C log } P + 13.33(\pm 1.79)$ $n = 6, \quad r^2 = 0.858, \quad q^2 = 0.475, \quad s = 0.256$
<b>QSAR Model 2</b>	$\text{Log } 1/K_i = -0.53(\pm 0.25)\text{CMR} + 20.72(\pm 4.97)$ $n = 7, \quad r^2 = 0.860, \quad q^2 = 0.708, \quad s = 0.306$
<b>QSAR Model 3</b>	$\text{Log } 1/\text{IC}_{90} = 0.49(\pm 0.21)\text{C log } P + 3.01(\pm 1.74)$ $n = 7, \quad r^2 = 0.874, \quad q^2 = 0.733, \quad s = 0.276$
<b>QSAR Model 4</b>	$\text{Log } 1/\text{IC}_{90} = 0.56(\pm 0.29)\text{CMR} + 4.12(\pm 5.82)$ $n = 6, \quad r^2 = 0.875, \quad q^2 = 0.576, \quad s = 0.307$
<b>QSAR Model 5</b>	$\text{Log } 1/T = 0.95(\pm 0.16)\text{C log } P - 10.67(\pm 1.28)$ $n = 7, \quad r^2 = 0.979, \quad q^2 = 0.945, \quad s = 0.203$
<b>QSAR Model 6</b>	$\text{Log } 1/T = 0.98(\pm 0.17)\text{CMR} - 22.75(\pm 3.55)$ $n = 7, \quad r^2 = 0.976, \quad q^2 = 0.939, \quad s = 0.219$
<b>Molecular Descriptor</b>	<p>Access the following web-servers to compute molecular descriptors: <a href="#">MoDel</a> and <a href="#">e-dragon</a></p> <p>Clog P range = 5.45–9.15; CMR range = 17.85 – 21.28; Clog P versus CMR (<math>r^2 = 0.922</math>); ClogP is the calculated partition coefficient in octanol/water and is a measure of hydrophobicity; CMR is the calculated molar refractivity for the whole molecule, and is a measure of volume and polarizability; MR is calculated as follows : <math>(n^2-1/n^2+2) (MW/d)</math>, where n is the refractive index, MW is the molecular weight, and d is the density of a substance; L is the Verloop's sterimol parameter that defines substituents' length.</p>

Reference	A mechanistic study of 3-aminoindazole cyclic urea HIV-1 protease inhibitors using comparative QSAR. <i>Bioorganic &amp; Medicinal Chemistry</i> 12 (2004) 5819–5831
-----------	--

Target Species	Human immunodeficiency virus 1
Chemical Type	P1/P1' substituted symmetrical aminoindazole analogs of cyclic urea
Mode of Action	Inhibitor
QSAR Model 1	$\text{Log } 1/K_i = -0.35(\pm 0.12)\text{C log } P + 12.95(\pm 0.95)$ $n = 10, \quad r^2 = 0.851, \quad q^2 = 0.780, \quad s = 0.202, \quad \text{outlier: } 4\text{-CH}_3$
QSAR Model 2	$\text{Log } 1/K_i = -0.37(\pm 0.11)\text{CMR} + 17.62(\pm 2.28)$ $n = 10, \quad r^2 = 0.877, \quad q^2 = 0.825, \quad s = 0.184, \quad \text{outlier: } 4\text{-CH}_3$
QSAR Model 3	$\text{Log } 1/\text{IC}_{90} = 0.28(\pm 0.11)\text{C log } P + 4.28(\pm 0.83)$ $n = 10, \quad r^2 = 0.813, \quad q^2 = 0.659, \quad s = 0.181, \quad \text{outlier: } 3\text{-C}(\text{CH}_3)_3$
QSAR Model 4	$\text{Log } 1/\text{IC}_{90} = 0.29(\pm 0.10)\text{CMR} + 0.47(\pm 2.08)$ $n = 10, \quad r^2 = 0.844, \quad q^2 = 0.728, \quad s = 0.166, \quad \text{outlier: } 3\text{-C}(\text{CH}_3)_3$
QSAR Model 5	$\text{Log } 1/T = 0.56(\pm 0.16)\text{C log } P - 8.15(\pm 1.30)$ $n = 11, \quad r^2 = 0.867, \quad q^2 = 0.776, \quad s = 0.302$
QSAR Model 6	$\text{Log } 1/T = 0.59(\pm 0.16)\text{CMR} - 15.50(\pm 3.29)$ $n = 11, \quad r^2 = 0.878, \quad q^2 = 0.793, \quad s = 0.290$
Molecular Descriptor	Access the following web-servers to compute molecular descriptors: <a href="#">MoDel</a> and <a href="#">e-dragon</a>

	Clog P range = 5.45–9.62; CMR range = 17.85 – 21.56; Clog P versus CMR ( $r^2 = 0.986$ ); ClogP is the calculated partition coefficient in octanol/water and is a measure of hydrophobicity; CMR is the calculated molar refractivity for the whole molecule, and is a measure of volume and polarizability; MR is calculated as follows : $(n^2-1/n^2+2) (MW/d)$ , where n is the refractive index, MW is the molecular weight, and d is the density of a substance; L is the Verloop's sterimol parameter that defines substituents' length.
Reference	A mechanistic study of 3-aminoindazole cyclic urea HIV-1 protease inhibitors using comparative QSAR. <i>Bioorganic &amp; Medicinal Chemistry</i> 12 (2004) 5819–5831

Target Species	Human immunodeficiency virus 1
Chemical Type	Nonsymmetrical 3-aminoindazoles
Mode of Action	Inhibitor
QSAR Model 1	$\text{Log } 1/K_i = -0.73(\pm 0.31)\text{C log } P + 15.26(\pm 2.04)$ $n = 5, r^2 = 0.950, q^2 = 0.859, s = 0.091$ outliers: CH <sub>2</sub> -2-naphthyl, CH <sub>2</sub> -cy-C <sub>3</sub> H <sub>5</sub>
QSAR Model 2	$\text{Log } 1/K_i = -0.78(\pm 0.76)\text{CMR} + 22.79(\pm 12.0)$ $n = 5, r^2 = 0.780, q^2 = 0.210, s = 0.200$ outliers: CH <sub>2</sub> -2-naphthyl, CH <sub>2</sub> C <sub>6</sub> H <sub>5</sub>
QSAR Model 3	$\text{Log } 1/\text{IC}_{90} = 1.27(\pm 0.64)\text{C log } P + 15.35(\pm 4.21)$ $n = 5, r^2 = 0.930, q^2 = 0.800, s = 0.189$ outliers: CH <sub>2</sub> -2-naphthyl, CH <sub>2</sub> -cy-C <sub>3</sub> H <sub>5</sub>
QSAR Model 4	$\text{Log } 1/\text{IC}_{90} = 0.22(\pm 0.36)\text{CMR} + 3.56(\pm 5.95)$ $n = 5, r^2 = 0.553, q^2 = -0.234, s = 0.274$ outliers: CH <sub>2</sub> -cy-C <sub>4</sub> H <sub>7</sub> , C <sub>6</sub> H <sub>13</sub>
QSAR Model 5	$\text{Log } 1/T = 0.15(\pm 0.13)\text{C log } P - 6.05(\pm 2.18)$ $n = 5, r^2 = 0.814, q^2 = 0.516, s = 0.100$ outliers: CH <sub>2</sub> -cy-C <sub>4</sub> H <sub>7</sub> , C <sub>6</sub> H <sub>13</sub>
QSAR Model 6	$\text{Log } 1/T = 0.31(\pm 0.37)\text{CMR} - 5.50(\pm 2.46)$ $n = 5, r^2 = 0.708, q^2 = 0.136, s = 0.182$ outliers: CH <sub>2</sub> -cy-C <sub>4</sub> H <sub>7</sub> , C <sub>5</sub> H <sub>11</sub>

<b>Molecular Descriptor</b>	<p>Access the following web-servers to compute molecular descriptors: <a href="#">MoDel</a> and <a href="#">e-dragon</a></p> <p>Clog P range = 5.63–7.52; CMR range = 15.32 – 18.26; Clog P versus CMR (<math>r^2 = 0.669</math>) ClogP is the calculated partition coefficient in octanol/water and is a measure of hydrophobicity; CMR is the calculated molar refractivity for the whole molecule, and is a measure of volume and polarizability; MR is calculated as follows : <math>(n^2-1/n^2+2) (MW/d)</math>, where n is the refractive index, MW is the molecular weight, and d is the density of a substance; L is the Verloop's sterimol parameter that defines substituents' length.</p>
<b>Reference</b>	A mechanistic study of 3-aminoindazole cyclic urea HIV-1 protease inhibitors using comparative QSAR. <i>Bioorganic &amp; Medicinal Chemistry</i> 12 (2004) 5819–5831

<b>Target Species</b>	Human immunodeficiency virus 1
<b>Chemical Type</b>	Nonsymmetrical P2/P2' substituted 3-aminoindazole cyclic urea compounds
<b>Mode of Action</b>	Inhibitor
<b>QSAR Model 1</b>	$\text{Log } 1/K_i = -0.47(\pm 0.15)\text{Clog } P + 13.50(\pm 1.09)$ <p><math>n = 8, r^2 = 0.900, q^2 = 0.819, s = 0.121</math>  outliers: <math>R_1 = 4\text{-C}_2\text{H}_5, R_2 = \text{CH}_2\text{C}_6\text{H}_5; R_1 = 4\text{-C}_2\text{H}_5, R_2 = \text{C}_4\text{H}_9</math></p>
<b>QSAR Model 2</b>	$\text{Log } 1/K_i = -0.30(\pm 0.14)\text{CMR} + 15.32(\pm 2.42)$ <p><math>n = 8, r^2 = 0.813, q^2 = 0.651, s = 0.142</math>  outliers: <math>R_1 = 4\text{-C}_2\text{H}_5, R_2 = \text{CH}_2\text{C}_6\text{H}_5; R_1 = 3, 5\text{-di-CH}_3, R_2 = \text{C}_4\text{H}_9</math></p>
<b>QSAR Model 3</b>	$\text{Log } 1/\text{IC}_{90} = 0.23(\pm 0.15)\text{C log } P + 4.72(\pm 1.10)$ <p><math>n = 6, r^2 = 0.822, q^2 = 0.530, s = 0.111</math>  outliers: <math>R_1 = 4\text{-CH}_3, R_2 = \text{CH}_2\text{C}_6\text{H}_5; R_1 = 3, 5\text{-di-CH}_3, R_2 = \text{CH}_2\text{C}_6\text{H}_5;</math>  <math>R_1 = 3\text{-CH}_3, R_2 = \text{C}_4\text{H}_9</math></p>
<b>QSAR Model 4</b>	$\text{Log } 1/\text{IC}_{90} = 0.32(\pm 0.16)\text{CMR} + 1.03(\pm 2.69)$

	$n = 7, r^2 = 0.840, q^2 = -0.705, s = 0.116$ outliers: $R_1 = 4\text{-C}_2\text{H}_5, R_2 = \text{CH}_2\text{C}_6\text{H}_5; R_1 = 3, 5\text{-di-CH}_3, R_2 = \text{CH}_2\text{C}_6\text{H}_5$
<b>QSAR Model 5</b>	$\text{Log } 1/T = 0.52(\pm 0.21)C \log P - 7.69(\pm 1.55)$ $n = 9, r^2 = 0.808, q^2 = 0.695, s = 0.215$
<b>QSAR Model 6</b>	$\text{Log } 1/T = 0.44(\pm 0.18)\text{CMR} - 11.37(\pm 3.02)$ $n = 9, r^2 = 0.807, q^2 = 0.697, s = 0.215$
<b>Molecular Descriptor</b>	Access the following web-servers to compute molecular descriptors: <a href="#">MoDel</a> and <a href="#">e-dragon</a> Clog P range = 6.34–8.40; CMR range = 15.45 – 18.43; Clog P versus CMR ( $r^2 = 0.665$ ); ClogP is the calculated partition coefficient in octanol/water and is a measure of hydrophobicity; CMR is the calculated molar refractivity for the whole molecule, and is a measure of volume and polarizability; MR is calculated as follows : $(n^2-1/n^2+2) (MW/d)$ , where n is the refractive index, MW is the molecular weight, and d is the density of a substance; L is the Verloop's sterimol parameter that defines substituents' length.
<b>Reference</b>	A mechanistic study of 3-aminoindazole cyclic urea HIV-1 protease inhibitors using comparative QSAR. <i>Bioorganic &amp; Medicinal Chemistry</i> 12 (2004) 5819–5831

<b>Target Species</b>	Human immunodeficiency virus 1
<b>Chemical Type</b>	3-aminoindazole cyclic urea derivatives
<b>Mode of Action</b>	Inhibitor
<b>QSAR Model 1</b>	$\text{Log } 1/K_i = -0.34(\pm 0.07)C \log P + 12.82(0.53)$ $n = 28, r^2 = 0.801, q^2 = 0.771, s = 0.195$ outliers: $R_1 = \text{H}, R_2/R_3 = 3\text{-NH}-(\text{CH}_2)_4\text{-indazole};$ $R_1 = 4\text{-CH}_3, R_2/R_3 = 3\text{-NH}_2\text{-indazole}; R_1 = \text{H}, R_2 = \text{CH}_2\text{-2-naphthyl},$ $R_3 = 3\text{-NH}_2\text{-indazole}; R_1 = \text{H}, R_2 = \text{C}_6\text{H}_{13}, R_3 = 3\text{-NH}_2\text{-indazole}$

<p>QSAR Model 2</p>	$\text{Log } 1/\text{IC}_{90} = 0.46(\pm 0.11)\text{C log } P + 1.23(\pm 0.28)I_1 - 0.19(\pm 0.10)L_4 + 3.61(\pm 0.78)$ <p><math>n = 27, \quad r^2 = 0.833, \quad q^2 = 0.773, \quad s = 0.234</math></p> <p>outliers: <math>R_1 = 3\text{-CMe}_3, \quad R_2/R_3 = 3\text{-NH}_2\text{-indazole}; R_1 = \text{H}, \quad R_2 = \text{C}_5\text{H}_{11},</math>  <math>R_3 = 3\text{-NH}_2\text{-indazole}; R_1 = \text{H}, \quad R_2 = \text{C}_6\text{H}_{13}, R_3 = 3\text{-NH}_2\text{-indazole};</math>  <math>R_1 = 3,5\text{-di-Me}, \quad R_2 = \text{CH}_2\text{C}_6\text{H}_5, R_3 = 3\text{-NH}_2\text{-indazole}</math></p>
<p>QSAR Model 3</p>	$\text{Log } 1/T = 0.78(\pm 0.15)\text{C log } P + 1.17(\pm 0.40)I_1 - 9.56(\pm 1.25)$ <p><math>n = 27, \quad r^2 = 0.808, \quad q^2 = 0.750, \quad s = 0.360</math></p> <p>outliers: <math>R_1 = 4\text{-C}_4\text{H}_9, \quad R_2/R_3 = 3\text{-NH}_2\text{-indazole};</math>  <math>R_1 = 3\text{-(CH}_3)_3, \quad R_2/R_3 = 3\text{-NH}_2\text{-indazole}; R_1 = \text{H}, \quad R_2 = \text{C}_6\text{H}_{13},</math>  <math>R_3 = 3\text{-NH}_2\text{-indazole}; R_1 = 4\text{-C}_2\text{H}_5, \quad R_2 = \text{C}_6\text{H}_5, R_3 = 3\text{-NH}_2\text{-indazole}</math></p>
<p>Molecular Descriptor</p>	<p>Access the following web-servers to compute molecular descriptors: <a href="#">MoDel</a> and <a href="#">e-dragon</a></p> <p>ClogP is the calculated partition coefficient in octanol/water and is a measure of hydrophobicity; CMR is the calculated molar refractivity for the whole molecule, and is a measure of volume and polarizability; MR is calculated as follows : <math>(n^2-1/n^2+2) (MW/d)</math>, where n is the refractive index, MW is the molecular weight, and d is the density of a substance; L is the Verloop's sterimol parameter that defines substituents' length.</p>
<p>Reference</p>	<p>A mechanistic study of 3-aminoindazole cyclic urea HIV-1 protease inhibitors using comparative QSAR. <i>Bioorganic &amp; Medicinal Chemistry</i> 12 (2004) 5819–5831</p>

<p>Target Species</p>	<p>Human immunodeficiency virus 1</p>
<p>Chemical Type</p>	<p>Nonsymmetrical 3-aminoindazole cyclic urea</p>
<p>Mode of Action</p>	<p>Inhibitor</p>
<p>QSAR Model 1</p>	$\text{Log } 1/\text{IC}_{90} = 8.46(\pm 3.17)\text{C log } P - 0.58(\pm 0.22)\text{C log } P^2 - 23.23(\pm 11.54)$



	$n = 8, \quad r^2 = 0.906, \quad q^2 = 0.721, \quad s = 0.119$ optimum $C \log P = 7.315$ (7.181–7.437) outliers: $R_1 = 3\text{-CH}_3, \quad R_2 = \text{C}_4\text{H}_9; R_1 = 4\text{-C}_2\text{H}_5, \quad R_2 = \text{C}_4\text{H}_9$
<b>QSAR Model 2</b>	$\text{Log } 1/\text{IC}_{90} = 0.082(\pm 0.020)C \log P + 5.90(\pm 0.14)$ $n = 4, \quad r^2 = 0.994, \quad q^2 = 0.977, \quad s = 0.008$ outliers: $R_1 = 3\text{-CH}_3, \quad R_2 = \text{CH}_2\text{C}_6\text{H}_5; R_1 = 4\text{-C}_2\text{H}_5, \quad R_2 = \text{CH}_2\text{C}_6\text{H}_5$
<b>Molecular Descriptor</b>	Access the following web-servers to compute molecular descriptors: <a href="#">MoDel</a> and <a href="#">e-dragon</a> ClogP is the calculated partition coefficient in octanol/water and is a measure of hydrophobicity; CMR is the calculated molar refractivity for the whole molecule, and is a measure of volume and polarizability; MR is calculated as follows : $(n^2-1/n^2+2)$ (MW/d), where n is the refractive index, MW is the molecular weight, and d is the density of a substance; L is the Verloop's sterimol parameter that defines substituents' length.
<b>Reference</b>	A mechanistic study of 3-aminoindazole cyclic urea HIV-1 protease inhibitors using comparative QSAR. <i>Bioorganic &amp; Medicinal Chemistry</i> 12 (2004) 5819–5831

<b>Target Species</b>	Human immunodeficiency virus 1
<b>Chemical Type</b>	$3\text{-}(\text{S}\text{-}(\text{CH}_2)_n\text{-C}_6\text{H}_5)$ , $6\text{-C}_6\text{H}_5$ , $6'\text{-R}$ (hydrophobic) substituted 4-hydroxy-5,6-dihydro pyran-2-ones
<b>Mode of Action</b>	Inhibitor
<b>QSAR Model 1</b>	$\text{Log}(1/\text{IC}_{50}) = 1.41(\pm 0.36)C \log P - 0.62(\pm 0.24)B5_R - 1.16(\pm 0.51)I_0 + 1.38(\pm 1.08)$ $n = 28, \quad r = 0.901, \quad r^2 = 0.812, \quad q^2 = 0.715, \quad s = 0.287$
<b>Molecular Descriptor</b>	Access the following web-servers to compute molecular descriptors: <a href="#">MoDel</a> and <a href="#">e-dragon</a> ClogP is the calculated partition coefficient in octanol/water and is a measure of the hydrophobicity of the molecule. It explains: (a) hydrophobic interactions between ligand and receptor, and (b)

	<p>random walk process in movement of the drug molecule in the organism from site of injection to sites of action.</p> <p>CMR is the calculated molar refractivity for the whole molecule and is a measure of volume and polarizability. MR is calculated as follows : <math>(n^2 - 1/n^2 + 2) (MW/d)</math>, where n is the refractive index, MW is the molecular weight, and d is the density of a substance.</p> <p>B5 is the Verloop's sterimol parameter that defines maximum width of the substituents. The indicator variable I is assigned the value of 1 or 0 for special affects that cannot be parameterized and has been explained wherever used.</p>
Reference	From SAR to comparative QSAR: role of hydrophobicity in the design of 4-hydroxy-5,6-dihydropyran-2-ones HIV-1 protease inhibitors. <i>Bioorganic &amp; Medicinal Chemistry</i> 13 (2005) 4078–4084.

Target Species	Human immunodeficiency virus 1
Chemical Type	3-(S-(CH <sub>2</sub> ) <sub>n</sub> -C <sub>6</sub> H <sub>5</sub> ), 6-C <sub>6</sub> H <sub>5</sub> , 6'-R (polar) substituted 4-hydroxy-5,6-dihydro pyran-2-ones
Mode of Action	Inhibitor
QSAR Model 1	$\text{Log}(1/IC_{50}) = 2.47(\pm 1.21)\text{CMR} + 1.58(\pm 0.84)I_{\text{COOH}} - 23.03(\pm 14.33)$ $n = 6, r = 0.972, r^2 = 0.945, q^2 = 0.661, s = 0.276$
Molecular Descriptor	<p>Access the following web-servers to compute molecular descriptors: <a href="#">MoDel</a> and <a href="#">e-dragon</a></p> <p>ClogP is the calculated partition coefficient in octanol/water and is a measure of the hydrophobicity of the molecule. It explains: (a) hydrophobic interactions between ligand and receptor, and (b) random walk process in movement of the drug molecule in the organism from site of injection to sites of action.</p> <p>CMR is the calculated molar refractivity for the whole molecule and is a measure of volume and polarizability. MR is calculated as follows : <math>(n^2 - 1/n^2 + 2) (MW/d)</math>, where n is the refractive index, MW is the molecular weight, and d is the density of a substance.</p> <p>B5 is the Verloop's sterimol parameter that defines maximum width of the substituents. The</p>

	indicator variable I is assigned the value of 1 or 0 for special affects that cannot be parameterized and has been explained wherever used.
<b>Reference</b>	From SAR to comparative QSAR: role of hydrophobicity in the design of 4-hydroxy-5,6-dihydropyran-2-ones HIV-1 protease inhibitors. <i>Bioorganic &amp; Medicinal Chemistry</i> 13 (2005) 4078–4084

<b>Target Species</b>	Human immunodeficiency virus 1
<b>Chemical Type</b>	3-(S-(2R',5R''-C <sub>6</sub> H <sub>5</sub> )), 6-C <sub>6</sub> H <sub>5</sub> , 6'-R (hydrophobic) substituted 4-hydroxy-5,6-dihydro-pyran-2-ones
<b>Mode of Action</b>	Inhibitor
<b>QSAR Model 1</b>	$\text{Log}(1/\text{IC}_{50}) = -0.28(\pm 0.23)\text{Clog}P + 0.73(\pm 0.24)B5_{R'} - 0.92(0.40)I_R + 7.67(\pm 1.45)$ $n = 17, r = 0.892, r^2 = 0.797, q^2 = 0.654, s = 0.255$
<b>Molecular Descriptor</b>	<p>Access the following web-servers to compute molecular descriptors: <a href="#">MoDel</a> and <a href="#">e-dragon</a></p> <p>ClogP is the calculated partition coefficient in octanol/water and is a measure of the hydrophobicity of the molecule. It explains: (a) hydrophobic interactions between ligand and receptor, and (b) random walk process in movement of the drug molecule in the organism from site of injection to sites of action.</p> <p>CMR is the calculated molar refractivity for the whole molecule and is a measure of volume and polarizability. MR is calculated as follows : <math>(n^2 - 1/n^2 + 2) (MW/d)</math>, where n is the refractive index, MW is the molecular weight, and d is the density of a substance.</p> <p>B5 is the Verloop's sterimol parameter that defines maximum width of the substituents. The indicator variable I is assigned the value of 1 or 0 for special affects that cannot be parameterized and has been explained wherever used.</p>
<b>Reference</b>	From SAR to comparative QSAR: role of hydrophobicity in the design of 4-hydroxy-5,6-dihydropyran-2-ones HIV-1 protease inhibitors. <i>Bioorganic &amp; Medicinal Chemistry</i> 13 (2005) 4078–4084

<b>Target Species</b>	Human immunodeficiency virus 1
<b>Chemical Type</b>	3-S-R'', 6-C <sub>6</sub> H <sub>5</sub> , 6'-R substituted 4-hydroxy-5,6-dihydro-pyran-2-ones
<b>Mode of Action</b>	Inhibitor
<b>QSAR Model 1</b>	$\text{Log}(1/\text{IC}_{50}) = 0.82(\pm 0.60)\text{Clog}P - 0.07(\pm 0.06)\text{Clog}P^2 + 0.47(\pm 0.19)\text{CMR} - 1.28(\pm 2.93)$ $n = 57, r = 0.850, r^2 = 0.722, q^2 = 0.676, s = 0.436$ $\text{Optimum Clog}P (\log P_0) = 6.345$
<b>Molecular Descriptor</b>	<p>Access the following web-servers to compute molecular descriptors: <a href="#">MoDel</a> and <a href="#">e-dragon</a></p> <p>ClogP is the calculated partition coefficient in octanol/water and is a measure of the hydrophobicity of the molecule. It explains: (a) hydrophobic interactions between ligand and receptor, and (b) random walk process in movement of the drug molecule in the organism from site of injection to sites of action.</p> <p>CMR is the calculated molar refractivity for the whole molecule and is a measure of volume and polarizability. MR is calculated as follows : <math>(n^2 - 1/n^2 + 2) (\text{MW}/d)</math>, where n is the refractive index, MW is the molecular weight, and d is the density of a substance.</p> <p>B5 is the Verloop's sterimol parameter that defines maximum width of the substituents. The indicator variable I is assigned the value of 1 or 0 for special affects that cannot be parameterized and has been explained wherever used.</p>
<b>Reference</b>	From SAR to comparative QSAR: role of hydrophobicity in the design of 4-hydroxy-5,6-dihydropyran-2-ones HIV-1 protease inhibitors. <i>Bioorganic &amp; Medicinal Chemistry</i> 13 (2005) 4078–4084